Our innovation model

Preventing, diagnosing and treating the majority of pathologies in most species has always been part of our DNA. Our innovation model, which spans biologicals, pharmaceuticals, diagnostics, petfood and pet care, is based on four pillars: 

Infographie_rubrique_notre_modele_innovation-450x407_EN.jpg

Listening to our customers

Our teams listen to our customers, and this has always been the foundation of our innovation to better serve those who care for animals every day. Our innovations focus on meeting the current and emerging needs of veterinarians, farmers and pet owners: improving diagnosis, expanding the range of preventive and therapeutic treatments for pathologies, and facilitating veterinary practice and animal care to improve compliance.

Technological advances in veterinary medicine

In veterinary medicine, unlike human health, innovation is not just the result of basic research. That's why we have always focused our investments and the work of our R&D teams on applied research and development, fostering synergies between field teams and researchers to find the best solutions for animals and those who care for them. We also open up new avenues for innovation through our culture of constant technological monitoring: partnerships with local universities, public and private research laboratories and biotech companies.

An ever-changing regulatory environment

In response to public demand, regulatory requirements are regularly tightened around the world. In order to set the framework for our innovations, which take between ten and fifteen years to develop, we constantly monitor current developments and future changes and integrate them into our research and development process.

CSR, a pillar of Virbac innovation

At Virbac, all our decisions, discoveries and actions are undertaken in a spirit of sharing and responsibility towards all living beings. This is why, more than ever, our innovation model takes into account the expectations and developments of society. For example, we are working to promote a more modern and ethical approach to companion animal reproduction and are developing new medicines that promote the rational use of antibiotics. We are also making significant investments in biology, pet care and petfood, which are key drivers of prevention, as part of a holistic approach.

SOURCES OF INNOVATION AT VIRBAC 

Our innovation ecosystem is built around: 

  • firstly, our technical expertise, particularly in formulation and biological techniques, which enables us to use our R&D to develop high value-added medicines and vaccines;

  • secondly, our ongoing exploration of licensing opportunities, to obtain rights to use our technologies and products. By facilitating rapid access to technological advances, this process enables us to bring new healthcare solutions to those who care for animals.
INVESTMENTS 

About 9% of annual revenues reinvested in R&D+licensing
 
R&D WORKFORCE  

About 700 employees worldwide (by the end of 2023)
 
REGISTRATION

Nearly 200 new product dossiers per year on average (including 140 marketing authorizations)